Imatinib regulatory update

The U.K.'s NICE issued a preliminary appraisal for Glivec imatinib from Novartis for the adjuvant treatment of gastrointestinal stromal tumors (GISTs) after

Read the full 228 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE